To: 5.1.2e [5.1.2e@rivm.nl]
Cc: 5.1.2e [5.1.2e@rivm.nl]; 5.1.2e [5.1.2e@rivm.nl]; 5.1.2e [5.1.2e@finddx.org]
From: 5.1.2e
Sent: Thur 9/3/2020 1:20:58 PM
Subject: Re: protocol for antigen test validation?
Received: Thur 9/3/2020 1:21:20 PM

Hi 5.1.2e
I've cc'd 5.1.2e, 5.1.2e to give you some guidance on the standard evaluations. 5.1.2e is on leave this week so will get back to you next week.

All the best
5.1.2e

5.1.2e
5.1.2e
FIND

On Sep 3, 2020, at 1:47 PM, 5.1.2e <5.1.2e@rivm.nl> wrote:

Hi 5.1.2e

Quick question: several labs in the Netherlands have started or are on the brink of validating antigen tests. Does FIND have a standard protocol for this that we could share to facilitate standardized data collection and sharing within the country and internationally?

Thanks 5.1.2e

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen* begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to *health and sustainability*

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender's email address and know the content is safe.

The FIND Geneva office has reopened, but please be advised that many staff continue to work mainly from home, on account of the COVID-19 pandemic